Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06328621
Other study ID # 19594
Secondary ID NCI-2021-0588119
Status Recruiting
Phase
First received
Last updated
Start date July 2, 2021
Est. completion date June 15, 2029

Study information

Verified date March 2024
Source City of Hope Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study examines the biological and social determinants that may increase the risk for lung cancer in patients and never-smoking individuals. Biological characteristics of a person can include their genetics and social determinants of a person can include their education, income, and environment, all of which can impact their health. Information collected in this study may help increase early detection of lung cancer.


Description:

PRIMARY OBJECTIVE: I. To assess the frequency of germline cancer susceptibility mutations in affected and unaffected individuals who have a personal or family history suggestive of high lung cancer risk. EXPLORATORY OBJECTIVES: I. To assess the frequency of abnormal radiographic findings in high-risk individuals unaffected with cancer who undergo low-dose computed tomography (CT) screening. II. Use patient survey and medical record data to explore the associations between social determinants of health, biological risk factors, family history and lung cancer incidence. III. To determine the sensitivity and specificity of liquid biopsy for detection of lung cancer in a never-smoking population. OUTLINE: Participants complete a survey over 40-45 minutes at baseline and undergo collection of blood samples at a scheduled clinical or research blood draw. Participants' medical records are also reviewed. Participants not diagnosed with lung cancer (i.e. "unaffected"), undergo a low-dose computerized tomography (CT) scan over 20 minutes.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date June 15, 2029
Est. primary completion date June 15, 2029
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Have had clinical germline genetic testing and/or have consented or expressed a willingness to consent to the City of Hope (COH) General Research Protocol COH IRB # 07047 - Age >= 18 years - Willing to have about 30 mL of blood (approximately 2 tablespoons) drawn during the aspiration visit - Speak English, Spanish, or Mandarin - Lung cancer patients: meeting at least one of the following criteria: - Be a never-smoker with lung cancer (excludes atypical/typical carcinoid and small cell tumors) - Be diagnosed with lung cancer =< 50 years of age - Have a germline alteration known/suspected to be associated with elevated lung cancer risk - Have a strong family history of lung cancer (>= one first, second or third degree relative with never-smoking lung cancer, >= three first, second or third degree relative with lung cancer in one lineage [side of the family], >= one first, second or third degree relative diagnosed with lung cancer under the age of 50. Patients may also be considered eligible if they meet the family history criteria in part and have a truncated family structure [e.g., only one first and one second degree relative with lung cancer in a small family]) - Unaffected patients (i.e., those without a lung cancer diagnosis and other cancer diagnosis for the past 5 years) who are at least 50 years of age or at most age 10 years younger than the first case of lung cancer in the family, meeting at least one of the following criteria: - Have a germline alteration known/suspected to be associated with elevated lung cancer risk - Have a strong family history of lung cancer (>= one first, second or third degree relative with never-smoking lung cancer, >= three first, second or third degree relative with lung cancer in one lineage [side of the family], >= one first, second or third degree relative diagnosed with lung cancer under the age of 50. Patients may also be considered eligible if they meet the family history criteria in part and have a truncated family structure [e.g., only one first and one second degree relative with lung cancer in a small family]) - Of East Asian descent with any family history of lung cancer - Documented informed consent of the participant Exclusion Criteria: - Unable to provide informed consent - Patients who fall under the unaffected cohort criteria but received chest imaging (except chest x-ray) within the last year

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Biospecimen Collection
Undergo collection of blood samples
Computed Tomography
Undergo low-dose CT
Other:
Electronic Health Record Review
Review of medical records
Survey Administration
Complete survey

Locations

Country Name City State
United States City of Hope Medical Center Duarte California

Sponsors (2)

Lead Sponsor Collaborator
City of Hope Medical Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Frequency of abnormal radiographic findings Will assess the frequency of abnormal radiographic findings in high-risk individuals unaffected with cancer who undergo low-dose computed tomography (CT) screening. Will summarize data related to the frequency of abnormal radiographic findings in high-risk individuals who undergo low-dose CT screening. Through study completion, an average of 5 years
Other Associations between molecular phenotypes, social determinants of health, and the presence of lung cancer and related outcomes Identification of associations of social determinants of health and risk factors with lung cancer using lung cancer cases and non cases (survey and medical record data). Up to study completion
Other Liquid biopsy (LB) test sensitivity Calculated by comparing the LB results with known cancer status. Results will be reported with their corresponding 95% confidence intervals. Through study completion, an average of 5 years
Other LB test specificity Calculated by comparing the LB results with known cancer status. Results will be reported with their corresponding 95% confidence intervals. Through study completion, an average of 5 years
Other LB test positive predictive value Calculated by comparing the LB results with known cancer status. Results will be reported with their corresponding 95% confidence intervals. Through study completion, an average of 5 years
Other LB test negative predictive value Calculated by comparing the LB results with known cancer status. Results will be reported with their corresponding 95% confidence intervals. Through study completion, an average of 5 years
Other LB test accuracy comparing LB genetic mutations to those found on next generation sequencing (NGS) LB test sensitivity and specificity, will be calculated by comparing the LB results with known cancer status. In addition to sensitivity and specificity, we will also examine other confusion matrix statistics, such as positive predictive value, negative predictive value, and test accuracy. Results will be reported with their corresponding 95% confidence intervals. Through study completion, an average of 5 years
Primary Frequency of germline alterations We will explore the relationships between variables, examining correlations (Pearson or Spearman where appropriate). Summarization of data using univariate distributions of the outcomes of interest (presence of lung cancer and molecular phenotypes) and their bivariate distributions with social determinants of health will be carried out. We will examine whether financial hardship, low levels of education, and traffic proximity are associated with presence of lung cancer and molecular phenotypes by using T-tests to compare means and Fisher's exact test to compare proportions. We will also conduct logistic regression modeling to adjust for relevant covariates like race/ethnicity, age, and sex. If appropriate, we will use standard techniques such as sensitivity analyses or multiple imputation to handle missing data. Through study completion, an average of 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT04931017 - Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer Phase 2
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Not yet recruiting NCT06038526 - Evaluation of Canakinumab in High-Risk Former-Smokers Phase 2
Terminated NCT02856581 - Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes Phase 3
Completed NCT04922697 - Educational Intervention for the Promotion of Knowledge and Preventive Health Behaviors Related to Personal Air Pollution Exposure, The Air Study N/A
Recruiting NCT04644952 - The Rise in Robotic Atypical Segmentectomies
Completed NCT01896778 - Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer N/A
Recruiting NCT05407168 - Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool N/A
Completed NCT04267874 - Black Raspberry Nectar for the Prevention of Lung Cancer, BE WELL Study Early Phase 1
Recruiting NCT02408861 - Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Recruiting NCT03709953 - Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma Phase 2
Active, not recruiting NCT03267524 - Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers N/A
Recruiting NCT04147494 - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues Early Phase 1
Completed NCT02237183 - Iloprost in Preventing Lung Cancer in Former Smokers Phase 1
Recruiting NCT04783168 - Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study N/A
Completed NCT04635761 - Awareness, Information, and Resources for Lung Cancer Screening Program for Community-Partnered Lung Cancer Screening N/A
Recruiting NCT06445192 - Evaluating the Impact of a Virtually Supervised Exercise Intervention and Group Counseling on Inflammation and the Microbiome of Smokers at High Risk for Lung Cancer, BE FIT Trial N/A
Active, not recruiting NCT03164486 - First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide Early Phase 1
Recruiting NCT05802186 - Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study N/A
Active, not recruiting NCT01696968 - Screening for Lung Cancer in Older Patients (PLCO Screening Trial) N/A